ALTHX Stock Overview
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Theranexus Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.52 |
| 52 Week High | €1.35 |
| 52 Week Low | €0.46 |
| Beta | 2.35 |
| 11 Month Change | -16.50% |
| 3 Month Change | -22.52% |
| 1 Year Change | -56.27% |
| 33 Year Change | -91.40% |
| 5 Year Change | -78.04% |
| Change since IPO | -96.83% |
Recent News & Updates
Shareholder Returns
| ALTHX | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 2.4% | -3.7% | -0.06% |
| 1Y | -56.3% | 6.2% | -2.5% |
Return vs Industry: ALTHX underperformed the French Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: ALTHX underperformed the French Market which returned -2.5% over the past year.
Price Volatility
| ALTHX volatility | |
|---|---|
| ALTHX Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.1% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALTHX's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALTHX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 12 | Mathieu Charvériat | www.theranexus.com |
Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.
Theranexus Société Anonyme Fundamentals Summary
| ALTHX fundamental statistics | |
|---|---|
| Market cap | €4.00m |
| Earnings (TTM) | -€3.08m |
| Revenue (TTM) | €2.27m |
1.8x
P/S Ratio-1.3x
P/E RatioIs ALTHX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTHX income statement (TTM) | |
|---|---|
| Revenue | €2.27m |
| Cost of Revenue | €3.78m |
| Gross Profit | -€1.51m |
| Other Expenses | €1.57m |
| Earnings | -€3.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -66.68% |
| Net Profit Margin | -136.00% |
| Debt/Equity Ratio | -85,117.4% |
How did ALTHX perform over the long term?
See historical performance and comparison